|
| Vaccine | Sarcoma histology | Number of patients | Immune response | Results |
|
| Irradiated autologous tumor cells [69] | Various pediatric | 16 | Not reported | 16.6 m versus 8.2 m survival (skin test responders) |
|
| Dendritic cell pulsed with autologous tumor lysate [70] | Various pediatric | 10 | Not reported | One response in patient with fibrosarcoma |
|
| Dendritic cell pulsed with peptides from tumor specific translocation breakpoints and E7 [71] | Metastatic Ewing’s family of tumors or alveolar rhabdomyosarcoma | 30/52 initiated vaccine after standard therapy | 39% with immune response to translocation breakpoint
25% with E7-specific response | 5-year OS: 31% for all patients versus 43% for patients initiating immunotherapy |
|
| 105AD7 (CD55 target) [72] | Osteosarcoma | 28 patients within 1–6 months of chemotherapy | 20/28 (71%) showed T cell proliferation response in vitro to 105AD7
9/28 (32%) weak antibody response to CD55 | 2 patients with possible clinical responses, alive and disease free 5.8 and 6.5 years from time of diagnosis |
|
| Dendritic vaccine pulsed with synthetic tumor specific peptide [73] | Posttransplant, residual tumor (synovial, Ewing’s) | 5 | DTH response against tumor lysate in 1 patient | 1 patient complete response, 77 months |
|
| Peptide encompassing SYT-SSX [74] | Synovial | 6 | Peptide specific CTLs generated in 4 patients | Suppression of tumor progression 1 patient |
|
| SYT-SSX derived peptide [75] | Synovial | 20 | 9 showed twofold increase in CTLs in tetramer analysis | 1/9 stable disease (received vaccine with peptide alone)
6/12 stable disease (received vaccine with incomplete Freund’s adjuvant) |
|
